TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

Name: TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use
Published: 2005
License: Public Domain

Tibotec Pharmaceuticals, Ireland · 2005

ClinicalTrials.gov · Datasets · License: Public Domain · 2005

Open Source ↗

hiv infection, tmc125, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, tmc125-c227, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

Related documents